These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. Simonetti G; Padella A; do Valle IF; Fontana MC; Fonzi E; Bruno S; Baldazzi C; Guadagnuolo V; Manfrini M; Ferrari A; Paolini S; Papayannidis C; Marconi G; Franchini E; Zuffa E; Laginestra MA; Zanotti F; Astolfi A; Iacobucci I; Bernardi S; Sazzini M; Ficarra E; Hernandez JM; Vandenberghe P; Cools J; Bullinger L; Ottaviani E; Testoni N; Cavo M; Haferlach T; Castellani G; Remondini D; Martinelli G Cancer; 2019 Mar; 125(5):712-725. PubMed ID: 30480765 [TBL] [Abstract][Full Text] [Related]
29. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160 [TBL] [Abstract][Full Text] [Related]
30. Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML. Kempf JM; Weser S; Bartoschek MD; Metzeler KH; Vick B; Herold T; Völse K; Mattes R; Scholz M; Wange LE; Festini M; Ugur E; Roas M; Weigert O; Bultmann S; Leonhardt H; Schotta G; Hiddemann W; Jeremias I; Spiekermann K Sci Rep; 2021 Mar; 11(1):5838. PubMed ID: 33712646 [TBL] [Abstract][Full Text] [Related]
31. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia. Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323 [TBL] [Abstract][Full Text] [Related]
32. The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor. Pettirossi V; Venanzi A; Spanhol-Rosseto A; Schiavoni G; Santi A; Tasselli L; Naccari M; Pensato V; Pucciarini A; Martelli MP; Drexler H; Falini B; Tiacci E Leukemia; 2023 Feb; 37(2):473-477. PubMed ID: 36635390 [No Abstract] [Full Text] [Related]
33. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair. Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682 [TBL] [Abstract][Full Text] [Related]
34. FOXM1 contributes to treatment failure in acute myeloid leukemia. Khan I; Halasi M; Patel A; Schultz R; Kalakota N; Chen YH; Aardsma N; Liu L; Crispino JD; Mahmud N; Frankfurt O; Gartel AL JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089730 [TBL] [Abstract][Full Text] [Related]
35. The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. Tiacci E; Grossmann V; Martelli MP; Kohlmann A; Haferlach T; Falini B Haematologica; 2012 Jan; 97(1):3-5. PubMed ID: 22210327 [No Abstract] [Full Text] [Related]
36. A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations. Li X; Xu F; Wu LY; Zhao YS; Guo J; He Q; Zhang Z; Chang CK; Wu D Sci Rep; 2020 Jan; 10(1):826. PubMed ID: 31964915 [TBL] [Abstract][Full Text] [Related]
37. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Zhang H; Savage S; Schultz AR; Bottomly D; White L; Segerdell E; Wilmot B; McWeeney SK; Eide CA; Nechiporuk T; Carlos A; Henson R; Lin C; Searles R; Ho H; Lam YL; Sweat R; Follit C; Jain V; Lind E; Borthakur G; Garcia-Manero G; Ravandi F; Kantarjian HM; Cortes J; Collins R; Buelow DR; Baker SD; Druker BJ; Tyner JW Nat Commun; 2019 Jan; 10(1):244. PubMed ID: 30651561 [TBL] [Abstract][Full Text] [Related]
38. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549 [TBL] [Abstract][Full Text] [Related]
39. Molecular pathogenesis of AML: translating insights to the clinic. Levine RL Best Pract Res Clin Haematol; 2013 Sep; 26(3):245-8. PubMed ID: 24309525 [TBL] [Abstract][Full Text] [Related]
40. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Ali D; Jönsson-Videsäter K; Deneberg S; Bengtzén S; Nahi H; Paul C; Lehmann S Eur J Haematol; 2011 Mar; 86(3):206-15. PubMed ID: 21114538 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]